Arvelle Therapeutics GmbH

Europe's biotechs have always held their own when it comes to scientific innovation but despite the tricky climate for financing, there are plenty of firms that have the potential to go from discovery

Health technology assessment (HTA) body NICE has issued draft guidance recommending that Ontozry (cenobamate), from Arvelle Therapeutics , should be made available on the National Health Service in E

SK Biopharmaceuticals Co., Ltd has reported a sharp rise in first-quarter sales and shifted to an operating profit on the back of rising prescriptions of Xcopri (cenobamate) in the US and the receipt

The Pink Sheet’s regularly updated list of products containing new active substances that have been approved for marketing in the EU under the centralized authorization procedure now includes three